USA-based healthcare giant Johnson & Johnson (NYSE: JNJ) has announced the publication of key Phase III data for nipocalimab in The Lancet Neurology.
J&J is testing the investigational FcRn blocker in a broad population of antibody positive patients with generalized myasthenia gravis (gMG).
Data show the Vivacity-MG3 study met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement over 24 weeks. The safety profile was also positive.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze